Therapy Rationale for Mineralocorticoid-Receptor Antagonists, Acetazolamide and a Switch of Therapy in Nonresponders in Central Serous Chorioretinopathy-Reference-Cited by-同舟云学术

Therapy Rationale for Mineralocorticoid-Receptor Antagonists, Acetazolamide and a Switch of Therapy in Nonresponders in Central Serous Chorioretinopathy

Published:2017-04 Issue:3 Volume:33 Page:141-148
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Rübsam Anne¹,Thieme Claudia E.¹,Schlomberg Juliane¹,Winterhalter Sibylle¹,Müller Bert¹,Joussen Antonia M.¹,Stübiger Nicole¹

Affiliation:

1. Department of Ophthalmology, Charité–Universitätsmedizin Berlin, Berlin, Germany.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jop.2016.0068

Reference35 articles.

1. Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy

2. Long-term Follow-up of Idiopathic Central Serous Chorioretinopathy by Fluorescein Angiography

3. Clinical, fluorescein angiographic and demographic aspects in central serous chorioretinopathy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical predictive factors and imaging biomarkers of treatment response to half dose PDT in patients with chronic central serous chorioretinopathy;Photodiagnosis and Photodynamic Therapy;2024-08

2. Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis;Eye;2021-01-07

3. Efficacy of mineralocorticoid receptor antagonist for central serous chorioretinopathy: a meta-analysis;International Ophthalmology;2020-07-06

4. Central serous chorioretinopathy: Towards an evidence-based treatment guideline;Progress in Retinal and Eye Research;2019-11

5. Oral medications for central serous chorioretinopathy: a literature review;Eye;2019-09-16